Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, by Type (Hereditary Transthyretin Amyloidosis (hATTR), and Wild Type Transthyretin Amyloidosis (wtATTR)), by Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), RNAi therapy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 748.80 million in 2020 and is expected to exhibit a CAGR of 31.1% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Ongoing clinical trials are expected to boost the market growth. For instance, Eidos Therapeutics, a clinical-stage biotech company developing novel, genetically targeted therapies, is developing AG10 800 mg, a TTR stabilizer for the treatment of transthyretin amyloid cardiomyopathy. The trial is in Phase III of evaluating AG10 800 mg compared to placebo in subjects with symptomatic transthyretin amyloid cardiomyopathy. This interventional trial started in March 2019 and the study is expected to be completed in May 2023.

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 63.96 million infected individuals worldwide as of December 3, 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Moreover, the COVID-19 pandemic has impacted the supply of raw materials and potent compounds, which are used for manufacturing drugs for transthyretin amyloid cardiomyopathy (ATTR-CM), which is expected to hamper the market growth in near future.

Browse 35 Market Data Tables and 33 Figures spread through 160 Pages and in-depth TOC on “Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market – by Type (Hereditary Transthyretin Amyloidosis (hATTR), and Wild Type Transthyretin Amyloidosis (wtATTR)), by Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), RNAi therapy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027”

To know the latest trends and insights prevalent in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/transthyretin-amyloid-cardiomyopathy-treatment-market-4321

Rising cases of transthyretin amyloid cardiomyopathy (ATTR-CM) among the geriatric population is driving growth of the market. For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in October 2016, the US Census Bureau, reports that the percentage of the population >65 years was ~12.4% in 2000 and >26% in 2016, along with this the diagnosis of wild type transthyretin amyloidosis (wtATTR) is also increasing.

Key Takeaways of the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market:

  • The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is expected to exhibit a CAGR of 31.1% during the forecast period, owing to rising incidence of transthyretin amyloid cardiomyopathy (ATTR-CM). For instance, according to an article- - Transthyretin Cardiac Amyloidosis in Older Americans, published by to the National Center for Biotechnology Information (NCBI), an article published in October 2016 , valine-to-isoleucine mutation is at position 122 (Val122Ile), and has a prevalence of ~4% in African Americans.
  • Among type, the wild type transthyretin amyloidosis (wtATTR) segment held a dominant position in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2019 owing to rising number of transthyretin amyloid cardiomyopathy (ATTR-CM) cases. For instance, according to an article- - Transthyretin Cardiac Amyloidosis in Older Americans, published by to the National Center for Biotechnology Information (NCBI), an article published in October 2016, transthyretin amyloidosis (wtATTR) accounts for 48% of all the transthyretin amyloid (ATTR) cases in the U.S.
  • Among drug type, transthyretin stabilizers segment held a dominant position in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2019, owing to its effective indication and rising drug approvals for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). For instance, in May 2019, FoldRx, a subsidiary of Pfizer Inc. received U.S. Food & Drug Administration (USFDA) approval for its Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of transthyretin mediated amyloidosis (ATTR-CM) in adults.
  • Among distribution channel, hospitals & clinics segment held a dominant position in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2019, owing to rising hospital visits. For instance, according to an article-according to the National Center for Biotechnology Information (NCBI), an article - Transthyretin Cardiac Amyloidosis in Older Americans, published by to the National Center for Biotechnology Information (NCBI) , an article published in October 2016, , 13% of subjects were hospitalized with heart failure and preserved ejection fraction (HFpEF), had transthyretin amyloidosis (wtATTR) cardiac amyloid.
  • Key players operating in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. among others.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo